Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 53.50
+0.25 (0.47%)
Jul 30, 2026, 3:35 PM HKT
Shanghai Henlius Biotech Market Cap
Shanghai Henlius Biotech has a market cap or net worth of 28.94 billion as of July 29, 2026. Its market cap has decreased by -26.35% in one year.
Market Cap
28.94B
Enterprise Value
32.01B
Revenue
7.42B
Ranking
n/a
PE Ratio
31.69
Stock Price
53.50
ChartMarket Cap Chart
Since September 25, 2019, Shanghai Henlius Biotech's market cap has increased from 26.66B to 28.94B, an increase of 8.56%. That is a compound annual growth rate of 1.21%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 30, 2026 | 28.94B | -6.66% |
| Dec 31, 2025 | 31.01B | 140.72% |
| Dec 31, 2024 | 12.88B | 70.50% |
| Dec 29, 2023 | 7.55B | 8.59% |
| Dec 30, 2022 | 6.96B | -41.95% |
| Dec 31, 2021 | 11.98B | -53.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| RemeGen | 66.59B |
| Biocytogen Pharmaceuticals (Beijing) | 60.18B |
| 3SBio | 42.72B |
| Genscript Biotech | 36.79B |
| Shanghai Junshi Biosciences | 36.50B |
| InnoCare Pharma | 28.60B |
| Keymed Biosciences | 22.99B |
| Duality Biotherapeutics | 20.60B |